trending Market Intelligence /marketintelligence/en/news-insights/trending/oabqxd03ejlidxqrp8lgha2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AFT Pharmaceuticals sells noncore hospital products to Baxter

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AFT Pharmaceuticals sells noncore hospital products to Baxter

AFT Pharmaceuticals Ltd. divested its noncore hospital products in New Zealand to Baxter International Inc. to focus on its higher margin over-the-counter offerings.

The company agreed to sell the assets to Baxter Healthcare, and said it expects to complete a similar agreement for noncore products in Australia within a few weeks.

AFT Pharmaceuticals will receive about NZ$5 million in cash from both transactions, which it plans to use for its international expansion plans.

The New Zealand divestment is expected to be completed on March 29, while the Australia divestment is expected to be completed in May or June.

The non-core products contribute about 7.5% of the company's operating revenue, AFT Pharmaceuticals said in a news release. CEO Hartley Atkinson noted that this revenue will be "more than replaced" within fiscal 2019, through the company's existing over-the-counter and new targeted hospital products.

As of March 20, US$1 was equivalent to NZ$1.39.